Do you still lose weight on the maintenance dose of Wegovy?

Does weight loss actually continue once you reach the maintenance dose?

A question our prescribers hear most weeks: "I've been on 2.4mg for a month and the scale is barely moving, is that normal?" The short answer is yes, slowing is normal, but stopping is not what the data show. In the STEP 1 trial, published in the New England Journal of Medicine, participants receiving 2.4mg semaglutide lost an average of around 15% of their body weight over 68 weeks. The titration period (roughly the first 16 weeks) accounts for only a fraction of that total. The steeper part of the curve sits in the months that follow, once the body settles at the maintenance dose.

Why does loss slow down? As you weigh less, your body needs fewer calories to function. Appetite suppression from semaglutide continues, but the deficit it creates shrinks alongside your body weight. This is well-understood physiology, not a sign the medicine has stopped working. Staying consistent with reduced-calorie eating and activity during this phase matters more, not less. You can read more about how Wegovy works as a treatment and what to expect across the course of therapy.

One practical note: the pace of loss is rarely linear. Some weeks nothing shifts; then several pounds move in a fortnight. Tracking a monthly average, rather than a daily number, gives a much cleaner picture of progress.

What happens to weight loss at 2.4mg versus the newer 7.2mg dose?

Until recently, 2.4mg was the ceiling for semaglutide in weight management. That changed in early 2026. The MHRA approved a 7.2mg maintenance dose in January 2026, with a dedicated single-dose pen confirmed in April 2026, making the UK one of the first countries to offer this option. Trial data for 7.2mg reported average weight loss of around 20.7% over 72 weeks, which narrows the gap considerably with tirzepatide at its highest dose. You can find the full detail on the 2.4mg maintenance dose page if you want to compare what people typically see at the standard level before considering escalation.

Whether 7.2mg is appropriate for you depends on how you've responded to 2.4mg and the prescriber's clinical assessment. The starting dose remains 0.25mg regardless of which maintenance level you're aiming for, and every step up is clinically reviewed. NHS England's guidance on weight-management injections sets out the broader clinical context, including how prescribers think about dose and response over time. Specific dose availability is always confirmed at consultation rather than assumed.

What if weight loss stalls or stops on the maintenance dose?

A genuine plateau (several months of no movement at all) is different from the natural slowing described above. NICE guidance for semaglutide notes that if fewer than 5% of body weight has been lost after six months on the maintenance dose, continuing treatment should be reviewed by the prescriber. This is not an automatic stop; it's a clinical conversation about whether to adjust, switch, or reassess. The question of what happens when you reach your goal weight on maintenance is a separate but related discussion worth reading if you're approaching that point.

Several factors can blunt response at maintenance: inconsistent dosing, significant changes to diet or activity, competing medications, or an underlying condition affecting metabolism. If progress has stalled, the right move is to raise it with your prescriber rather than assume the dose needs changing. Our clinical team reviews these situations regularly, see our clinical team's approach to ongoing weight management support. You can also check frequently asked questions for answers to common concerns between consultations.

How does the maintenance dose relate to the full Wegovy dosing schedule?

Semaglutide for weight management follows a structured escalation: 0.25mg, then 0.5mg, 1.0mg, 1.7mg, and finally the 2.4mg maintenance dose, each step roughly four weeks apart. The lower doses during titration are primarily about tolerability, giving the gut time to adjust and reducing the intensity of nausea and other gastrointestinal effects. They are not therapeutic targets in themselves. Our Wegovy doses overview explains each stage and what the prescriber is looking for before moving up.

The 1mg step often prompts questions because it matches the Ozempic dose used in type 2 diabetes. To be clear: Ozempic is licensed for diabetes, not weight loss, and the weight-management evidence base sits with Wegovy's licensed schedule. There is a more detailed explanation of how the 1.7mg Wegovy dose relates to Ozempic if that comparison has come up for you. Understanding where each dose sits in the schedule helps set realistic expectations for what the maintenance phase will feel like when you arrive there. The 1mg maintenance question is also addressed separately for those on lower doses by prescriber decision.

For anyone considering private treatment or wanting to understand all available options, our weight-loss treatment overview sets out the full picture clearly.